SignatureFD’s Disc Medicine IRON Stock Holding History

SignatureFD’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18	Closed	-$894	–	3342
2025 Q1	$894	Buy	+18	New	+$1K	﹤0.01%	3066

Other funds holding IRON

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SignatureFD's IRON Position: Q2 2025 in Review

SignatureFD sold out of Disc Medicine (IRON) in Q2 2025, closing a stake of 18 shares — an estimated $894 sold.

SignatureFD first reported a position in IRON in Q1 2025 and held it in 1 quarter. The position peaked at $894 in Q1 2025. 151 funds tracked by Wall St. Rank hold IRON as of Q2 2025.

SignatureFD reported no remaining Disc Medicine position as of Q2 2025 after selling out during the quarter.
SignatureFD sold 18 Disc Medicine shares in Q2 2025, an estimated $894.
SignatureFD first reported a position in Disc Medicine in Q1 2025 and held it in 1 quarter.
SignatureFD's Disc Medicine position peaked at $894 in Q1 2025.
151 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2025.

Based on SignatureFD's 13F filing for Q2 2025, filed 16 Jul 2025.